Lord Freyberg (CB)

My Lords, I support Amendment 211 moved by my noble friend Lady Kidron, which builds on earlier contributions in this place made by the noble Lords, Lord Mitchell, Lord Stevenson, Lord Clement-Jones, and myself, as long ago as 2018, about the need to maximise the social, economic and environmental value that may be derived from personal data of national significance and, in particular, data controlled by our NHS. The proposed definition of “sovereign data assets” is, in some sense, broad. However, the intent to recognise, protect and maximise their value in the public interest is readily inferred. The call for a transparent licensing regime to provide access to such assets and the mention of preferential access for individuals and organisations headquartered in the UK also make good sense, as the overarching aim is to build and maintain public trust in third-party data usage. Crucially, I fully support provisions that would require the Secretary of State to report on the value and anticipated financial return from sovereign data assets. Identifying a public body that considered itself able or willing to guarantee value for money proved challenging when this topic was last explored. For too long, past Governments have dithered and delayed over the introduction of provisions that explicitly recognise the need to account for and safeguard the investment made by taxpayers in data held by public and arm’s-length institutions and associated data infrastructure—something that we do as a matter of course where the tangible assets that the National Audit Office monitors and reports on are concerned. In recent weeks, the Chancellor of the Exchequer has emphasised the importance of recovering public funds “lost” during the Covid-19 pandemic. Yet this focus raises important questions about other potential revenue streams that were overlooked, particularly regarding NHS data assets. In 2019, Ernst & Young estimated that a curated NHS dataset could generate up to £5 billion annually for the UK while also delivering £4.6 billion in yearly patient benefits through improved data infrastructure. This begs the question: who is tracking whether these substantial economic and healthcare opportunities are being realised? Who is ensuring that these projected benefits—both financial and clinical—are actually flowing back into our healthcare system? As we enter the age of AI, public discourse often fixates on potential risks while overlooking a crucial opportunity—namely, the rapidly increasing value of publicly controlled data and its potential to drive innovation and insights. This raises two crucial questions. First, how might we capitalise on the upside of this technological revolution to maximise the benefits on behalf of the public? Secondly, and more specifically, how will Parliament effectively scrutinise any eventual trade deal entered into with, for example, the United States of America, which might focus on a more limited digital chapter, in the absence of either an accepted valuation methodology or a transparent licensing system for use in providing access to valuable UK data assets? Will the public, faced with a significant tax burden to improve public services and repeated reminders of the potential for data and technology to transform our NHS, trust the Government if they enable valuable digital assets to be stripped today only to be turned tomorrow into cutting-edge treatments that we can ill afford to purchase and that benefit companies paying taxes overseas? To my mind, there remains a very real risk that the UK, as my noble friend Lady Kidron, rightly stated, will inadvertently give away potentially valuable digital assets without there being appropriate safeguards in place. I therefore welcome the intent of Amendment 211 to put that right in the public interest.